2. Search Result
Search Result
Results for "

calcification

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

1

Peptides

1

Inhibitory Antibodies

8

Natural
Products

3

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0886
    β-Glycerophosphate disodium salt pentahydrate
    Maximum Cited Publications
    30 Publications Verification

    		 Phosphatase Endogenous Metabolite ERK Metabolic Disease Cancer
    β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .
    β-Glycerophosphate disodium salt pentahydrate
  • HY-126304
    β-Glycerophosphate disodium salt hydrate
    Maximum Cited Publications
    30 Publications Verification

    		 Phosphatase Endogenous Metabolite ERK Metabolic Disease
    β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .
    β-Glycerophosphate disodium salt hydrate
  • HY-B0561
    Spironolactone
    5+ Cited Publications

    SC9420

    		 Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca 2+ channels to exert antihypertensive effects .
    Spironolactone
  • HY-112499
    Menaquinone-7
    3 Publications Verification

    Vitamin K2-7; Vitamin K2(35); Vitamin MK-7

    		 TGF-beta/Smad Cardiovascular Disease
    Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7
  • HY-108611
    AACOCF3
    4 Publications Verification

    Arachidonyl trifluoromethyl ketone

    		 Phospholipase Cardiovascular Disease
    AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .
    AACOCF3
  • HY-B0302
    Etidronic acid
    1 Publications Verification

    Etidronate; HEDPA; HEDP

    		 Environmental Pollutants Apoptosis Metabolic Disease Cancer
    Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid
  • HY-B0302A
    Etidronic acid disodium
    1 Publications Verification

    Etidronate disodium; HEDPA disodium; HEDP disodium

    		 Apoptosis Metabolic Disease Cancer
    Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid disodium
  • HY-W015370
    L-Lysine hydrate
    5+ Cited Publications

    		 Endogenous Metabolite Others Inflammation/Immunology
    L-Lysine hydrate is an essential amino acid. L-Lysine hydrate can be research for vascular calcification (VC) and acute pancreatitis .
    L-Lysine hydrate
  • HY-103265
    ARL67156 trisodium
    3 Publications Verification

    FPL 67156 trisodium

    		 NTPDase Cardiovascular Disease Inflammation/Immunology
    ARL67156 (FPL 67156) trisodium is a selective small molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12?μM, respectively. ARL67156 trisodium can be used in the research of calcific aortic valve disease, asthma .
    ARL67156 trisodium
  • HY-171099
    SC-919

    LI-2124

    		 IPK Superfamily Cardiovascular Disease Endocrinology
    SC-919 is an orally active IP6K inhibitor, with an IC50 of < 5.2 nM against IP6K1, < 3.8 nM against IP6K2, and 0.65 nM against IP6K3. By inhibiting the activity of IP6K, SC-919 reduces intracellular IP7 levels, thereby suppressing XPR1-mediated cellular phosphate efflux. SC-919 increases intracellular phosphate and ATP levels while reducing phosphate entry into the bloodstream, thus decreasing plasma phosphate levels. SC-919 can be used in research related to chronic kidney disease and hyperphosphatemia .
    SC-919
  • HY-Y1324
    Sodium phosphate dibasic dodecahydrate

    Disodium hydrogen phosphate dodecahydrate; Disodium phosphate dodecahydrate

    		 Environmental Pollutants Biochemical Assay Reagents Endocrinology
    Phosphoric acid disodium dodecahydrate is an inorganic compound and food additive. Phosphoric acid disodium dodecahydrate promotes gel formation, improves food texture and thermal properties of materials. Phosphoric acid disodium dodecahydrate induces glomerular calcification. Phosphoric acid disodium dodecahydrate can be used in kidney disease research .
    Sodium phosphate dibasic dodecahydrate
  • HY-N6031
    Dendrophenol
    3 Publications Verification

    Moscatilin

    		 NF-κB Apoptosis COX HIF/HIF Prolyl-Hydroxylase Wnt β-catenin JNK Cardiovascular Disease Inflammation/Immunology Cancer
    Dendrophenol (Moscatilin) is a NF-κB inhibitor that inhibits inflammation. Dendrophenol exerts potent cytotoxic effect against tumor cells and induces cell cycle arrest and apoptosis. Dendrophenol has antitumor activity. In addition, Dendrophenol can inhibit vascular calcification by inhibiting the activation of WNT3/β-catenin .
    Dendrophenol
  • HY-14210
    TNAP-IN-1

    		Phosphatase Inflammation/Immunology
    TNAP-IN-1 (Compound 1) is a selective tissue-nonspecific alkaline phosphatase (TNAP) inhibitor, with an IC50 of 0.19 μM. TNAP-IN-1 can be used for the research of soft tissue calcification .
    TNAP-IN-1
  • HY-119093
    Halopemide
    1 Publications Verification

    		 Phospholipase Dopamine Receptor Neurological Disease Cancer
    Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .
    Halopemide
  • HY-109106A
    Upacicalcet sodium

    SK-1403; AJT240; PLS240

    		 CaSR Endocrinology
    Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca 2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .
    Upacicalcet sodium
  • HY-138822
    2,3-Diphospho-D-glyceric acid pentasodium salt

    2,3-DPG pentasodium salt

    		 Endogenous Metabolite Cardiovascular Disease
    2,3-Diphospho-D-glyceric acid (2,3-DPG) pentasodium salt is a hemoglobin binder and vascular calcification inhibitor that reduces the oxygen affinity of hemoglobin. 2,3-Diphospho-D-glyceric acid pentasodium salt also specifically delays the transformation of colloidal calciprotein particles into crystalline forms, thereby effectively inhibiting vascular smooth muscle cell calcification without affecting the normal formation of osteoid nodules in osteoblast-like cells. 2,3-Diphospho-D-glyceric acid pentasodium salt shows no cytotoxicity to tested cell lines and only weakly interferes with β-hematin formation mediated by glyceryl monopalmitate. 2,3-Diphospho-D-glyceric acid pentasodium salt can be used to study the pathological mechanisms of vascular calcification and malaria-related conditions .
    2,3-Diphospho-D-glyceric acid pentasodium salt
  • HY-103265B
    ARL67156 trisodium hydrate
    3 Publications Verification

    FPL 67156 trisodium hydrate

    		 NTPDase Cardiovascular Disease Inflammation/Immunology
    ARL67156 (FPL 67156) trisodium hydrate is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium hydrate is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma .
    ARL67156 trisodium hydrate
  • HY-135517
    RXP470.1

    RXP-470

    		 MMP Cardiovascular Disease
    RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification .
    RXP470.1
  • HY-103265D
    ARL67156 triethylamine
    3 Publications Verification

    FPL 67156 triethylamine

    		 NTPDase Cardiovascular Disease Inflammation/Immunology
    ARL67156 (FPL 67156) triethylamine is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 triethylamine is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively. ARL67156 triethylamine can be used in the research of disease like calcific aortic valve disease, asthma .
    ARL67156 triethylamine
  • HY-Y0308D
    Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339

    Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339

    		 Biochemical Assay Reagents Endocrinology
    Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms .
    Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339
  • HY-158791
    Enpp-1-IN-21

    		Phosphodiesterase (PDE) Metabolic Disease Cancer
    Enpp-1-IN-21 (compound 4g) is an inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), with IC50 values for ENPP1 and ENPP3 at 0.45 and 0.19 μM, respectively .
    Enpp-1-IN-21
  • HY-15872
    FTI-277

    		Farnesyl Transferase Ras ERK mTOR Caspase Apoptosis Akt PI3K Bacterial Cardiovascular Disease Neurological Disease Cancer
    FTI-277 is a farnesyltransferase (FTase) inhibitor. FTI-277 inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 activates caspase 3, upregulates Bim expression, induces cell apoptosis, suppresses regulatory T cell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification .
    FTI-277
  • HY-110038
    FTI-277 TFA

    		Farnesyl Transferase Ras ERK mTOR Apoptosis Caspase Akt PI3K Bacterial Cardiovascular Disease Neurological Disease Cancer
    FTI-277 TFA is a farnesyltransferase (FTase) inhibitor. FTI-277 TFA inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 TFA activates caspase 3, upregulates Bim expression, induces cell apoptosis, suppresses regulatory T cell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 TFA activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 TFA can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification .
    FTI-277 TFA
  • HY-W014606
    L-Lysine acetate
    5+ Cited Publications

    		 Endogenous Metabolite Others Inflammation/Immunology
    L-Lysine acetate is an essential amino acid. L-Lysine acetate can be research for vascular calcification (VC) and Acute pancreatitis .
    L-Lysine acetate
  • HY-153335
    Enpp-1-IN-16

    		Phosphodiesterase (PDE) Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders .
    Enpp-1-IN-16
  • HY-112499S
    Menaquinone-7-d7

    Vitamin K2-7-d7; Vitamin K2(35)-d7; Vitamin MK-7-d7

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Menaquinone-7-d7 is the deuterium labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors . Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS) .
    Menaquinone-7-d7
  • HY-112499R
    Menaquinone-7 (Standard)
    3 Publications Verification

    Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)

    		 Endogenous Metabolite Reference Standards Cardiovascular Disease
    Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7 (Standard)
  • HY-126304R
    β-Glycerophosphate disodium salt hydrate (Standard)

    		Reference Standards Phosphatase Endogenous Metabolite ERK Metabolic Disease
    β-Glycerophosphate disodium salt hydrate (Standard) is the analytical standard of β-Glycerophosphate disodium salt hydrate (HY-126304). This product is intended for research and analytical applications. β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.
    β-Glycerophosphate disodium salt hydrate (Standard)
  • HY-116307
    2-Thio-UTP

    		P2Y Receptor Cardiovascular Disease
    2-Thio-UTP is a selective P2Y2 inhibitor with an EC50 value of 50 nM. 2-Thio-UTP reduces pro-fibrotic gene expression and protein α-smooth muscle actin. 2-Thio-UTP has the potential for the research of calcific aortic valve stenosis (CAVS) .
    2-Thio-UTP
  • HY-P991677
    Efmirenpase alfa

    INZ-701

    		 Phosphodiesterase (PDE) Cardiovascular Disease Endocrinology
    Efmirenpase alfa is an Fc-ENPP1 fusion protein (human IgG1 Fc domain linked to a modified human ENPP1). Efmirenpase alfa has prolonged half-life and enhanced receptor affinity compared with native human ENPP1. Efmirenpase alfa can be used as an enzyme replacement therapy for ENPP1 deficiency such as arterial calcification and hypophosphatemic rickets research .
    Efmirenpase alfa
  • HY-124044
    ML 086

    		Phosphatase Cardiovascular Disease
    ML 086 is a highly selective PHOSPHO1 phosphatase inhibitor (IC50=0.14 μM). ML 086 is promising for research of hereditary vascular calcification disorders (e.g., generalized arterial calcification of infancy) and spinal ligament ossification .
    ML 086
  • HY-109106
    Upacicalcet

    SK-1403 free acid; AJT240 free acid; PLS240 free acid

    		 CaSR Endocrinology
    Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
    Upacicalcet
  • HY-112499S1
    Menaquinone-7-13C6

    Vitamin K2-7-13C6; Vitamin K2(35)-13C6; Vitamin MK-7-13C6

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Menaquinone-7- 13C6 is the 13C-labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors . Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS) .
    Menaquinone-7-13C6
  • HY-B0561S4
    Spironolactone-d6-1

    		Isotope-Labeled Compounds Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel Cardiovascular Disease Metabolic Disease Cancer
    Spironolactone-d6-1 is the deuterium labeled Spironolactone (HY-B0561). Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca 2+ channels to exert antihypertensive effects .
    Spironolactone-d6-1
  • HY-W014606R
    L-Lysine acetate (Standard)

    		Reference Standards Endogenous Metabolite Others Inflammation/Immunology
    L-Lysine (acetate) (Standard) is the analytical standard of L-Lysine (acetate). This product is intended for research and analytical applications. L-Lysine acetate is an essential amino acid. L-Lysine acetate can be research for vascular calcification (VC) and Acute pancreatitis .
    L-Lysine acetate (Standard)
  • HY-B0302R
    Etidronic acid,60% in water (Standard)

    Etidronate (Standard); HEDPA (Standard); HEDP (Standard)

    		 Apoptosis Reference Standards Metabolic Disease Cancer
    Etidronic acid,60% in water (Standard) is the analytical standard of Etidronic acid,60% in water. This product is intended for research and analytical applications. Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid,60% in water (Standard)
  • HY-W015370R
    L-Lysine hydrate (Standard)

    		Reference Standards Endogenous Metabolite Others Inflammation/Immunology
    Squalane (Standard) is the analytical standard of Squalane. This product is intended for research and analytical applications. Squalane, found in certain fish oils (especially shark liver oil), and some vegetable oils, is a saturated derivative of Squalene. Squalane shows anticancer, antioxidant, skin hydrating, and emollient activities .
    L-Lysine hydrate (Standard)
  • HY-119093R
    Halopemide (Standard)

    		Phospholipase Dopamine Receptor Neurological Disease Cancer
    Halopemide (Standard) is the analytical standard of Halopemide. This product is intended for research and analytical applications. Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .
    Halopemide (Standard)
  • HY-B0302AR
    Etidronic acid disodium (Standard)

    Etidronate disodium (Standard); HEDPA disodium (Standard); HEDP disodium (Standard)

    		 Reference Standards Apoptosis Metabolic Disease Cancer
    Etidronic acid (disodium) (Standard) is the analytical standard of Etidronic acid (disodium). This product is intended for research and analytical applications. Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid disodium (Standard)
  • HY-109106B
    (Rac)-Upacicalcet

    (Rac)-SK-1403 free acid; (Rac)-AJT240 free acid; (Rac)-PLS240 free acid

    		 CaSR Endocrinology
    (Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
    (Rac)-Upacicalcet
  • HY-P0109
    (S,S)-Z-FA-FMK

    		Cathepsin Others
    (S,S)-Z-FA-FMK is a cell-permeable, irreversible cathepsin B inhibitor. (S,S)-Z-FA-FMK blocks LPS-induced production of IL-1α and IL-1β. (S,S)-Z-FA-FMK can be used as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position .
    (S,S)-Z-FA-FMK
  • HY-P1775B
    Carbonic Anhydrase, Human

    		Endogenous Metabolite Metabolic Disease
    Carbonic Anhydrase, Human (EC 4.2.1.1) is a zinc metalloenzyme that catalyzes the hydration of carbon dioxide to form carbonic acid. Carbonic Anhydrase participates in a variety of important physiological processes, such as the maintenance of pH and carbon dioxide homeostasis, the transport of bicarbonate and carbon dioxide, biosynthetic reactions, bone resorption, calcification, and tumorigenesis.
    Carbonic Anhydrase, Human
  • HY-E70986
    Carbonic Anhydrase I, Human

    		Endogenous Metabolite Metabolic Disease
    Carbonic Anhydrase I, Human (EC 4.2.1.1) is a zinc metalloenzyme that catalyzes the hydration of carbon dioxide to form carbonic acid. Carbonic Anhydrase I participates in a variety of important physiological processes, such as the maintenance of pH and carbon dioxide homeostasis, the transport of bicarbonate and carbon dioxide, biosynthetic reactions, bone resorption, calcification, and tumorigenesis.
    Carbonic Anhydrase I, Human
  • HY-159978
    EOS789

    		Sodium Phosphate Cotransporter Metabolic Disease Inflammation/Immunology
    EOS789 is an orally active sodium-dependent phosphate transporter inhibitor, with IC50 values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC50 values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. EOS789 inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. EOS789 ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. EOS789 can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) .
    EOS789

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: